Human Growth Hormone Market Report (2023 to 2031) – Pfizer, Inc., Novo Nordisk Inc., AnkeBio Co. Ltd, and Eli Lilly and Company


Newark, New Castle, USA, June 18, 2023 (GLOBE NEWSWIRE) — Growth Plus Reports estimated the size of the global market for human growth hormone in 2022 to be worth US$ 4.4 billion, and it is expected that it will increase at a revenue CAGR of 8.4% to reach US$ 9.1 billion by 2031.

The global market for human growth hormone was analyzed and is expected to rise significantly in terms of revenue share during the forecast period. Children’s growth and development are significantly aided by human growth hormone (HGH). Additionally, it controls both children’s and adults’ metabolism, muscle and bone growth, and body composition.

Key Takeaways: 


  • The rise of growth hormone deficiency is driving the market revenue share.
  • The growing demand for anti-aging treatments has led to a surge in market demand.
  • The recombinant DNA technology has significantly improved the efficiency and scalability of HGH production.

Get a Sample Copy of the Research Report:

                                  Human Growth Hormone Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 4.4 billion
Revenue Forecast in 2031 US$ 9.1 billion
CAGR 8.4%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Indication, Route of Administration, Distribution Channel, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Human Growth Hormone Market: 

  • In February 2022, The European Commission granted marketing approval to Pfizer Inc. and OPKO Health Inc. for the once-weekly injection of next-generation long-acting recombinant human growth hormone NGENLATM (somatrogon), which is used to treat children and adolescents from the age of 3 who have growth disturbances caused by insufficient growth hormone secretion.

Competitive Landscape

A list of the prominent players operating in the global market for human growth hormones includes: 

  • Merck KGaA
  • Novo Nordisk Inc.
  • Pfizer, Inc
  • AnkeBio Co. Ltd
  • Eli Lilly and Company

Market Drivers and Restraints: 

The global human growth hormone market revenue is driven by the Increasing prevalence of growth hormone deficiency, growing demand for anti-aging treatments, technological advancements, and availability of government funding and favorable policies for research and development.  

However, due to high expenses and the availability of alternative treatment options, the human growth hormone market revenue growth is expected to be restrained. 

Market Segmentation: 

Segmentation By Indication

Based on the products, the growth hormone deficiency segment dominates the global human growth hormone market with the largest revenue share. This large revenue share is attributed to it as it is the primary and most prevalent indication for human growth hormone treatment, and there is a constant demand for growth hormone supply since many GHD patients require long-term human growth hormone therapy.

Segmentation By Route of Administration

Based on the route of administration, the parenteral segment dominates the global human growth hormone market with the largest revenue share. Growth hormones can be administered by the simple and practical intramuscular (IM) parenteral route, which is effective for administering human growth hormones and may improve patient compliance. This helps the segment’s revenue growth to rise rapidly.

Request for Customization –

Segmentation By Distribution Channel

Based on distribution channels, the hospital pharmacies segment accounts for the highest revenue share in the global human growth hormone market as for people with serious or persistent medical conditions, such as growth hormone deficiency, they can offer long-term human growth hormone therapy.

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global human growth hormone market. This large revenue share is due to the region having an advanced healthcare system with a high level of diagnosis and comprehension of these issues, which has an impact on the market’s strong demand for products containing human growth hormones.

Report Coverage 

Growth Plus Reports analyzed the global market for human growth hormones in-depth. We studied the fundamental market characteristics, significant investment sectors, regional growth analytics, revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Growth Hormone Deficiency
    2. Turner Syndrome
    3. Idiopathic Short Stature
    4. Prader-Willi Syndrome
    5. Others
    1. Parenteral
    2. Oral
    1. Hospital Pharmacies
    2. Retail Pharmacies 
    3. Online Pharmacies


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Lanadelumab Market by Age Group (Adult and Pediatric) – Global Outlook & Forecast 2023-2031

Dostarlimab-gxly Market by Cancer Type (Endometrial Cancer, Skin Cancer), End User (Hospital, Homecare Settings) – Global Outlook & Forecast 2023-2031

Prolactin Inhibitors Market by Drug (Bromocriptine, Cabergoline, Others), Indication (Hyperprolactinemia, Acromegaly, Type 2 Diabetes, Others) – Global Outlook & Forecast 2023-2031

Gastroprotective Drugs Market by Drug Class (Antacids, Histamine (H2) Receptor Antagonists), Application (Gastric and duodenal ulceration, Gastritis)– Global Outlook & Forecast 2023-2031

Erysipeloid Treatment Market by Drug Type (Erythromycin, Penicillin), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.